XOMA 052 Demonstrates Anti-Inflammatory Effects in Diabetes Animal Studies; Data Presented At ADA
Red Orbit (Free subscription) | 06/07/2008
SAN FRANCISCO, June 7, 2008 (PRIME NEWSWIRE) -- XOMA Ltd.
- add comment
- send to a friend
- Explore : Health
Red Orbit (Free subscription) | 06/07/2008
SAN FRANCISCO, June 7, 2008 (PRIME NEWSWIRE) -- XOMA Ltd.
PR News Wire (Free subscription) | 06/05/2008
... and Dermatologists expect its growth to continue, primarily at the expense of Enbrel. Genentech/Xoma's Raptiva and Astellas' Amevive are rarely used with a collective share of less than 10%. Despite the increased use of biologics, topical agents remain the most commonly prescribed therapy for psoriasis. Warner Chilcott's Taclonex, continues to hold its position as market leader among topical...